Anthropic's IPO filing is the best negotiating memo your procurement team will get this year

On 26 October 2026, at 9:00:11 in the morning Eastern time, Anthropic gave every company that buys Claude a negotiating document that its account managers would never have handed over voluntarily. The S-1 for its listing on the Nasdaq Global Select Market, under the ticker ANT, starts its risk factors on page 26. Early coverage from Unite.AI reports that those risk factors include "customer and distribution-channel concentration". If you run procurement for a company with a large Claude commitment, or you sell a product built on one, I think that phrase is worth more to you than the price range, which the filing still leaves blank.

Until now, every enterprise AI negotiation ran on the vendor's information. You knew what you paid. The account team knew what everyone paid, how many accounts carried the quarter and which resellers mattered most. A concentration disclosure is the first time Anthropic has had to tell outsiders, with lawyers from Wilson Sonsini and Freshfields checking the wording, how heavily its revenue leans on a small group of customers or channels. That changes your leverage in one of two ways. If a big share of revenue sits with a handful of giants, a mid-sized direct buyer is the diversification that Anthropic will want to show public investors next year. If revenue is spread wide, you learn that you are one of many and should stop paying for bespoke terms you will never use. Either way you walk into the room knowing something you did not know in September.

The cover page alone contains a detail I did not expect. Anthropic has created Class N common stock, held primarily by strategic business partners, with no votes and automatic conversion to Class A when sold to an unaffiliated party. In other words, some of the companies that may sit between you and the model as distributors also hold equity in it. If you buy Claude through a partner channel, I would want to know how much of that partner's interest lies in your discount and how much in Anthropic's share price, and I would ask them directly.

Timing matters because incentives change at listing. Before an IPO, I think a sales organisation wants booked revenue and recognisable logos to put in the roadshow. After it, every quarter's gross margin is picked over by analysts at the banks lined up on that cover, from Goldman Sachs to Macquarie, and the cheapest discounts are the first thing a new public company quietly withdraws. Buyers who lock a multi-year rate in the window between filing and trading are dealing with a sales team chasing logos; anyone who waits will be dealing with a finance team defending margin.

The sceptic in our office points out, fairly, that an S-1 rarely shows what any single customer pays, and that customer counts, retention rates and other key metrics in management's discussion are usually not audited. Calling this a complete, audited picture of enterprise AI pricing overstates it. I agree with the facts and disagree with the conclusion. You do not need your competitor's per-token rate. You need to know how badly the vendor needs you, and audited revenue plus a concentration disclosure in the financial statements tell you that better than any analyst note. The unaudited metrics still sit in a document the company can be sued over, which makes them harder to spin than a slide in a quarterly business review.

The governance section has its own message for buyers. The founders' Class F share carries 50.1% of the voting power on most matters, the Long-Term Benefit Trust elects directors who form a board majority, employees get voting-only Class E stock, and Anthropic will be a controlled company under Nasdaq rules. As a public benefit corporation it must balance shareholders' money against the interests of people affected by its conduct. I read that as a company insulated from activist investors demanding a price war, and equally insulated from activists demanding it squeeze customers harder. Pricing decisions will stay with the seven co-founders and the board they and the trust choose, so the person you negotiate with will be accountable to them first.

Before you sign any Claude renewal that runs past the listing date, pull the filing from EDGAR, find the concentration figures in the notes to the financial statements, and put them in front of your account executive in the first meeting. Then ask for a cap on annual price increases written into the contract for its full term, and get it signed before ANT starts trading.

Prompted by Anthropic, PBC - S-1 (Q2), sec.gov.